With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday, it is not clear whether Teva can execute his plan to return the ailing generics and specialty pharmaceuticals company to growth.

Teva's board and remaining management say they are committed to implementing the strategy Levin developed and presented to investors in December. However, Chairman Phillip Frost said disagreement over an unspecified aspect of implementing that strategy led the board and Levin to part - just two days after Levin publicly denied rumors he had threatened to resign.